Results 141 to 150 of about 424,818 (305)

Liquid biopsy‐based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis

open access: yesMolecular Oncology, EarlyView.
This schematic outlines the workflow from biomarker identification to duplex MethyLight assay validation for epithelial ovarian cancer diagnosis using cfDNA‐based liquid biopsy. Initial screening of hypermethylated CpG candidates (cg02957270, cg10061138 cg00480298, COL2A1) was performed in tissue using ARMS‐PCR, COBRA, qPCR and image analysis. Selected
Deepa Bisht   +3 more
wiley   +1 more source

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

open access: yesMolecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski   +12 more
wiley   +1 more source

Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials

open access: yes, 2015
Ronald L Van Heertum, Robert Scarimbolo, Robert Ford, Eli Berdougo, Michael O’Neal BioClinica Inc, Princeton, PA, USA Abstract: In the era of personalized medicine, diagnostic approaches are helping pharmaceutical and biotechnology sponsors ...
Scarimbolo R   +4 more
core  

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

open access: yesMolecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi   +11 more
wiley   +1 more source

Molecular Diagnostics

open access: yesHuman Genomics, 2011
Cassiman Jean-Jacques
doaj   +1 more source

The Importance of Brain Banks for Molecular Neuropathological Research: The New South Wales Tissue Resource Centre Experience

open access: yes, 2009
New developments in molecular neuropathology have evoked increased demands for postmortem human brain tissue. The New South Wales Tissue Resource Centre (TRC) at The University of Sydney has grown from a small tissue collection into one of the leading ...
Donna Sheedy   +7 more
core   +1 more source

Erythropoietin modulates hepatic inflammation, glucose homeostasis, and soluble epoxide hydrolase and epoxides in high‐fat diet‐induced obese mice

open access: yesFEBS Open Bio, EarlyView.
Erythropoietin administration suppresses hepatic soluble epoxide hydrolase (sEH) expression, leading to increased CYP‐derived epoxides. This is associated with a shift in hepatic macrophage polarization characterized by reduced M1 markers and increased M2 markers, along with reduced hepatic inflammation, suppressed hepatic lipogenesis, and attenuated ...
Takeshi Goda   +12 more
wiley   +1 more source

Applicability of mitotic figure counting by deep learning: a development and pan‐cancer validation study

open access: yesFEBS Open Bio, EarlyView.
In this study, we developed a deep learning method for mitotic figure counting in H&E‐stained whole‐slide images and evaluated its prognostic impact in 13 external validation cohorts from seven different cancer types. Patients with more mitotic figures per mm2 had significantly worse patient outcome in all the studied cancer types except colorectal ...
Joakim Kalsnes   +32 more
wiley   +1 more source

Molecular Diagnostics in Pathology [PDF]

open access: yesArchives of Pathology & Laboratory Medicine, 2018
openaire   +2 more sources

Advanced technologies and diagnostic spin-outs: an interview with Carl Borrebaeck. [Elektronisk resurs]

open access: yes, 2015
Interview with Professor Carl Borrebaeck DSc by Claire Raison (Commissioning Editor) Professor Carl Borrebaeck DSc, is the Director of CREATE Health (Lund, Sweden), a translational cancer center, previous Vice President of Lund University and specializes
Lund University., Borrebaeck, Carl,
core   +1 more source

Home - About - Disclaimer - Privacy